In the research in breast cancer cells, the combination of lapatinib, a dual HER2/neu and EGFR tyrosine kinase inhibitor, with INK128 prevented the two HER2 and HER3 phosphorylation induced by INK128 and generated synergistic induction of mobile Demise in several HER2-positive mobile strains immune to trastuzumab and lapatinib. In vivo https://thomast641inr4.ourabilitywiki.com/user